Assembly Biosciences (FRA:V7B) Interest Expense : €0.00 Mil (TTM As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Assembly Biosciences Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Assembly Biosciences's interest expense for the three months ended in Jun. 2024 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2024 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Assembly Biosciences's Operating Income for the three months ended in Jun. 2024 was € -11.34 Mil. Assembly Biosciences's Interest Expense for the three months ended in Jun. 2024 was € 0.00 Mil. GuruFocus does not calculate Assembly Biosciences's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Assembly Biosciences Interest Expense Historical Data

The historical data trend for Assembly Biosciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assembly Biosciences Interest Expense Chart

Assembly Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

Assembly Biosciences Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Assembly Biosciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Assembly Biosciences (FRA:V7B) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Assembly Biosciences's Interest Expense for the three months ended in Jun. 2024 was €0.00 Mil. Its Operating Income for the three months ended in Jun. 2024 was €-11.34 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2024 was €0.42 Mil.

Assembly Biosciences's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as

GuruFocus does not calculate Assembly Biosciences's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Assembly Biosciences Inc has enough cash to cover all of its debt. Its financial situation is stable.

Assembly Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Assembly Biosciences Inc (FRA:V7B) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

ASMB:USA

Address

331 Oyster Point Boulevard, Fourth Floor, South San Francisco, CA, USA, 94080

Website

https://www.assemblybio.com

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, that are designed to restore health to a dysbiotic microbiome. The firm's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Its program targets high-recurrence genital herpes associated with herpes simplex virus type 2 (HSV-2) infection and research programs focused on the discovery of novel antivirals to treat devastating viral diseases, including hepatitis delta virus (HDV) and transplant-related herpesviruses.

Assembly Biosciences Headlines

No Headlines